Fit-for-purpose ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive peripheral T cell lymphoma and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND filing exp. in 3Q19 for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Phase l or ll
Hematology, Immuno-Oncology, Oncology
100MM - 500MM
Antibodies, Platform Technology
Im Neuenheimer Feld 582
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Oktoberfest 2019 Wall Street "On Tap"
October 4, 2019
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by